

Open Payments Data Fact Sheet: Sept 30, 2014.

	(Revised)
Table 1: Entire Dataset (Identified + Deidentified Data)	
Categories	Total
Total Value	\$3.5 Billion*
Total Number of Records	4.4 Million*
Value per Record	\$795
Total Number of Physicians	546,000*
Total Number of Teaching Hospitals	1,360*
Number of Reporting Organizations	1,419

Table 2: Identified Data Only	
Categories	Total
Value	\$1.3 Billion*
Number of Records	2.7 Million*
Value per Record	\$481
Number of Physicians	360,000*
Number of Teaching Hospitals	873
Number of Reporting Organizations	1,379

Table 3: De-identified Data Only	
Categories	Total
Value	\$2.2 Billion* (63% of published)
Number of Records	1.7 Million* (39% of published)
Value per Record	\$1,294
Number of Covered Recipient Physicians	Not Published
Number of Teaching Hospitals	Not Published
Number of Reporting Organizations	1,114

Table: 4 Open Payments Data Not Published and Not Included Above.	
Categories	Total
Reason 1: Unresolved disputes at the end of review period	
Value of records	\$514 Million*
Number of records	9,000*
Value per Record	\$57,111
Reason 2: Delay in publication**	
Value of records	\$551 Million*
Number of records	190,000*
Value per Record	\$2,900
Totals	
Total Value=	\$1.1 Billion*
Total Number of records=	199,000*

Table 5: Review and Dispute of the September 30 publication

Categories	Totals
Number of Physicians that registered to Review and Dispute	26,000* (4.8%)
Number of Teaching Hospitals that registered to Review and Dispute	405* (29.8%)
Number of Records that were Disputed	12579 (0.3%)
Number of Unresolved disputes at the end of review period	9,000* (71.5%)
Number of Records that were Affirmed	17,994

Open Payments Data Fact Sheet provided by CMS, 9/30/2014.

– Edited by P Hasselbacher, KHPI.

Notes:

* asterisk indicates number was rounded by CMS.

- "Reported Entities" include all Applicable Manufacturers & Group Purchasing Organizations.
- Data "Not Published" is promised during a future reporting cycle.
- Delay in publication upon request by reporting entity for up to 4 years after approval, licensure, or clearance by FDA of drug, product, or device.